These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 9988400)

  • 21. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
    Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R
    J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
    Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
    PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome.
    Abramov Y; Barak V; Nisman B; Schenker JG
    Fertil Steril; 1997 Feb; 67(2):261-5. PubMed ID: 9022600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors Associated with Ovarian Hyperstimulation Syndrome (OHSS) Severity in Women With Polycystic Ovary Syndrome Undergoing IVF/ICSI.
    Sun B; Ma Y; Li L; Hu L; Wang F; Zhang Y; Dai S; Sun Y
    Front Endocrinol (Lausanne); 2020; 11():615957. PubMed ID: 33542709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome.
    Aboulghar MA; Mansour RT; Serour GI; El Helw BA; Shaarawy M
    Eur J Obstet Gynecol Reprod Biol; 1999 Nov; 87(1):81-5. PubMed ID: 10579621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.
    Rizk B; Aboulghar M; Smitz J; Ron-El R
    Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Preliminary study on the role of vascular endothelial growth factor in pathogenesis of ovarian hyperstimulation syndrome].
    Zhou C; Yu C; Zhuang G
    Zhonghua Fu Chan Ke Za Zhi; 2001 Nov; 36(11):654-6. PubMed ID: 11930688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome.
    Kobayashi H; Okada Y; Asahina T; Gotoh J; Terao T
    J Mol Endocrinol; 1998 Jun; 20(3):363-74. PubMed ID: 9687159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    BJOG; 2014 Jun; 121(7):848-55. PubMed ID: 24621101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study.
    Tan SL; Balen A; el Hussein E; Campbell S; Jacobs HS
    Fertil Steril; 1992 Aug; 58(2):378-83. PubMed ID: 1633906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome.
    Chen CD; Wu MY; Chen HF; Chen SU; Ho HN; Yang YS
    Fertil Steril; 1999 Aug; 72(2):286-92. PubMed ID: 10438997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moderate-to-severe ovarian hyperstimulation syndrome: A retrospective multivariate logistic regression analysis in Chinese patients.
    Ma T; Niu Y; Wei B; Xu L; Zou L; Che X; Wang X; Tang D; Huang R; Chen B
    Adv Clin Exp Med; 2020 Jan; 29(1):85-90. PubMed ID: 31990458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report.
    Krasnow JS; Berga SL; Guzick DS; Zeleznik AJ; Yeo KT
    Fertil Steril; 1996 Mar; 65(3):552-5. PubMed ID: 8774285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome.
    Neulen J; Yan Z; Raczek S; Weindel K; Keck C; Weich HA; Marmé D; Breckwoldt M
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1967-71. PubMed ID: 7775647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles.
    Lee TH; Liu CH; Huang CC; Wu YL; Shih YT; Ho HN; Yang YS; Lee MS
    Hum Reprod; 2008 Jan; 23(1):160-7. PubMed ID: 18000172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome.
    Pau E; Alonso-Muriel I; Gómez R; Novella E; Ruiz A; García-Velasco JA; Simón C; Pellicer A
    Hum Reprod; 2006 Jun; 21(6):1453-60. PubMed ID: 16488907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the ovulatory serum concentration of human chorionic gonadotropin on the incidence of ovarian hyperstimulation syndrome and success rates for in vitro fertilization.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Ross R; Morris S
    Fertil Steril; 2005 Jul; 84(1):93-8. PubMed ID: 16009163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum estradiol level and oocyte number in predicting severe ovarian hyperstimulation syndrome.
    Chen CD; Wu MY; Chao KH; Chen SU; Ho HN; Yang YS
    J Formos Med Assoc; 1997 Oct; 96(10):829-34. PubMed ID: 9343984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Relationship between letrozole administration during the luteal phase after oocyte retrieval and the early-stage ovarian hyperstimulation syndrome oocurrence].
    He Q; Xu J; Cui S; Li H; Zhang C
    Zhonghua Fu Chan Ke Za Zhi; 2014 Dec; 49(12):909-13. PubMed ID: 25608991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.